DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Okada M, Imagawa J, Tanaka H. et al.
DADI Trial Group, Japan. Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment.
Clin Lymphoma Myeloma Leuk 2018;
18 (05) 353-360.e1
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.